Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus

NCT04059198 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

5

Enrollment

INDUSTRY

Sponsor class

Stopped Evidence of liver injury in a separate Inarigavir study

Conditions

Hepatitis B
HBV
Hepatitis B, Chronic

Interventions

DRUG: Inarigivir soproxil
DRUG: Tenofovir alafenamide fumarate (TAF)

Sponsor

F-star Therapeutics, Inc.

Collaborators

[object Object]